Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +4.84%8 Quick Ratio is 2.37 as of Dec. 2025, which is 40% below its 10-year median of 3.97. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 853 Medical Devices & Instruments companies, Alamar Biosciences ranks better than 59.32% on this metric.
Alamar Biosciences (NAS:ALMR) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Alamar Biosciences Quick Ratio Related Terms
Alamar Biosciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Alamar Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences Quick Ratio Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
Quick Ratio
5.56
2.37
Alamar Biosciences Semi-Annual Data
Dec24
Dec25
Quick Ratio
5.56
2.37
ALMR vs UFPT, BFLY, ENOV: Quick Ratio Comparison
For the Medical Devices subindustry, Alamar Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Alamar Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences (ALMR) has a Quick Ratio of 2.37 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alamar Biosciences and its competitors. This is 40% below median its historical median of 3.97. Over the past decade, Alamar Biosciences' Quick Ratio has ranged from 2.37 to 5.56. According to the industry distribution chart, Alamar Biosciences ranks #347 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 40.7%.
Is Alamar Biosciences' Quick Ratio too high?
Alamar Biosciences' current Quick Ratio of 2.37 is 40% below median its 10-year median of 3.97. Over the past 10 years, this metric has ranged from a low of 2.37 to a high of 5.56. The Medical Devices & Instruments industry median Quick Ratio is 1.89. Alamar Biosciences' value of 2.37 is 25.4% above this industry median. Based on the distribution chart, Alamar Biosciences ranks #347 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Quick Ratio compare to UFPT and BFLY?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #347 out of 853 companies for Quick Ratio. This puts Alamar Biosciences in the upper half of its industry. The industry median Quick Ratio is 1.89. Alamar Biosciences' value of 2.37 is 25.4% above this benchmark. Historically, Alamar Biosciences' own Quick Ratio has ranged from 2.37 to 5.56 over the past decade. While the company's 10-year median is 3.97 vs. the industry median of 1.89, Alamar Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alamar Biosciences's current Quick Ratio of 2.37 is 25.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current Quick Ratio is 2.37, which is 40% below median its own 10-year median of 3.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Quick Ratio of 2.37. The current Quick Ratio is 2.37, which is 40% below median its 10-year median of 3.97 and 25.4% above the Medical Devices & Instruments industry median of 1.89. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Quick Ratio is 2.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score
Get the complete analysis for ALMR
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
